The Therapeutic Goods Administration (TGA) has launched a stakeholder survey to help inform its compliance activities for FY24 having previously flagged medicinal cannabis advertising as a priority in this financial year.
The survey asks respondents to identify “the most concerning non-compliance trends or issues relating to therapeutic goods” during CY22.
It asks for details of the non-compliant behaviour, the actual and potential harms associated with it, the frequency with which it was observed and whether it has increased or decreased in comparison with previous years.
It also asks for feedback on its FY23 priorities, including ensuring compliance from the medicinal cannabis industry and whether that continues to be an issue.
The regulator has issued a number of fines for alleged non-compliant advertising of medicinal cannabis in FY23 with Little Green Pharma, Cannatrek, MGC Pharmaceuticals, MiDispensary and CA Clinics among those penalised.
And last month, a new website launched encouraging users to report allegations of unethical business practice in the Australian medicinal cannabis space to the authorities.
Responses should be sent to the TGA’s regulatory compliance branch – rcbcompliancegovernance@health.gov.au – by COB on Monday April 3.
